Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

doi:10.1177/2047487317712419

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?

European journal of preventive cardiology - 1 Sept 2017

Sbrana Francesco, Dal Pino Beatrice, Bigazzi Federico, Ripoli Andrea, Passino Claudio, Gabutti Alessandra, Pasanisi Emilio M, Petersen Christina, Valleggi Alessandro, Todiere Giancarlo, Barison Andrea, Giannoni Alberto, Panchetti Luca, Becherini Francesco, Pianelli Mascia, Luciani Roberta, Sampietro Tiziana

Abstract excerpt

Background Familial hypercholesterolemia is the elective clinical condition that deserves the maximal personalisation in lipid-lowering therapy, especially in the presence of statin intolerance. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors represent a promising approach to lower low-density lipoprotein (LDL) cholesterol. Methods We enrolled 18 patients (mean age 62 ± 8 years, 72% men) affected...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Blood Component Removal

Share to Cholesterol, LDL

Share to Drug Substitution

Share to Hydroxymethylglutaryl-CoA Reductase Inhibitors

Share to Hyperlipoproteinemia Type II

Share to Proprotein Convertase 9

Share to Serine Proteinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 28555526
DOI: 10.1177/2047487317712419

Genes

PCSK9

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Statin intolerance in heterozygous familial hypercolesterolemia with cardiovascular disease: After PCSK-9 antibodies what else?PMID 28555526Read ↗

Anti-PCSK9 antibodies for the treatment of heterozygous familial hypercholesterolemia: patient selection and perspectives.Semantic proximity Read ↗

Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.Semantic proximity Read ↗

Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.Semantic proximity Read ↗

Familial Hypercholesterolemia: Although Identification Advances, Appreciation and Treatment Lag.Semantic proximity Read ↗

Lipoprotein Apheresis: An Established Therapeutic Modality for Homozygous Familial Hypercholesterolemia Patients Refractory to PCSK9 Inhibitors: A Case Report and Literature ReviewSemantic proximity Read ↗

Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.Semantic proximity Read ↗

Evolocumab in patients with homozygous familial hypercholesterolemia in India.Semantic proximity Read ↗

Homozygous familial hypercholesterolemia in a young woman with dual gene mutations of low-density lipoprotein receptor and proprotein convertase subtilisin/kexin type 9.Semantic proximity Read ↗

Update on the use of PCSK9 inhibitors in adults: Recommendations from an Expert Panel of the National Lipid Association.Semantic proximity Read ↗

PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies.Semantic proximity Read ↗

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPNSemantic proximity Read ↗

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolaemia: An expert consensus statement from ERKNet and ESPN.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.